SCHEMBL2819052

SCHEMBL2819052

COc1cccc(/C=C/c2nc3ccccn3c(=O)c2-c2cccc(OC(C)C)c2)c1OC1CCCC1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 2/20 0.36
KCNK9 Q9NPC2 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.34
LMNA P02545 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CNR2 P34972 1/20 0.34
MITF O75030 1/20 0.34
PTGDR Q13258 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
POLB P06746 1/20 0.32
MAPT P10636 3/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
PDE4D Q08499 1/20 0.32
TRPM8 Q7Z2W7 2/20 0.31
KMT2A Q03164 1/20 0.31
TP53 P04637 1/20 0.31
PIK3CA P42336 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2820040 0.93 KCNK3 (0.40) KCNK3KCNK9SMN1; SMN2LMNAL3MBTL1
SCHEMBL2819037 0.89 LMNA (0.39) SMN1; SMN2LMNAL3MBTL1POLBMAPT
SCHEMBL2819041 0.89 LMNA (0.39) SMN1; SMN2LMNAL3MBTL1POLBMAPT
SCHEMBL2820851 0.88 LMNA (0.36) KCNK3KCNK9SMN1; SMN2LMNAL3MBTL1
SCHEMBL2823839 0.86 MAOB (0.37) SMN1; SMN2LMNAL3MBTL1RXFP1MAPT
SCHEMBL2820866 0.86 MAOB (0.37) SMN1; SMN2LMNAL3MBTL1RXFP1MAPT
SCHEMBL2820681 0.85 LMNA (0.37) KCNK3KCNK9SMN1; SMN2LMNAL3MBTL1
SCHEMBL2818866 0.85 SMN1; SMN2 (0.38) SMN1; SMN2LMNAMITFRXFP1POLB
SCHEMBL2825545 0.85 LMNA (0.38) SMN1; SMN2LMNAL3MBTL1MAPTALDH1A1
SCHEMBL2825547 0.85 LMNA (0.38) SMN1; SMN2LMNAL3MBTL1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349846-B2 Fused pyrimidine derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2013-01-08 US claimed
US-20100292254-A1 Fused Pyrimidine Derivatives as Trpv3 Modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-11-18 US claimed
US-8349846-B2 Fused pyrimidine derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2013-01-08 US disclosed
US-8349846-B2 Fused pyrimidine derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2013-01-08 US disclosed
US-8349846-B2 Fused pyrimidine derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2013-01-08 US disclosed
US-20100292254-A1 Fused Pyrimidine Derivatives as Trpv3 Modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-11-18 US disclosed
US-20100292254-A1 Fused Pyrimidine Derivatives as Trpv3 Modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-11-18 US disclosed
US-20100292254-A1 Fused Pyrimidine Derivatives as Trpv3 Modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292254-A1 Fused Pyrimidine Derivatives as Trpv3 Modulators TRPV3, TRPV1, TRPV5 KCNK3 121/4885KCNK9 483/4885SMN1; SMN2 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.